Alnylam price target raised to $359 from $336 at BofA

BofA raised the firm’s price target on Alnylam (ALNY) to $359 from $336 and keeps a Buy rating on the shares. BofA conducted a survey with 25 cardiologists treating 3,150 ATTR-CM patients to better understand initial dynamics of the Amvuttra launch, with respondents indicating they have written 195 scripts since the launch with a ~50/50 split for newly diagnosed and switch patients, the analyst tells investors in a research note. Respondents expect Amvuttra could have ~29% share at peak and expect it to reach ~25% share over the next 24 months, BofA adds.